The Lancet Regional Health: Western Pacific最新文献

筛选
英文 中文
Trends of lipid-lowering drug utilization, treatment intensity and LDL-C target attainment in adults with diabetes and non-dialysis chronic kidney disease in Hong Kong 香港成人糖尿病及非透析慢性肾病患者的降脂药物使用趋势、治疗强度及LDL-C达标情况
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-10-01 DOI: 10.1016/j.lanwpc.2025.101696
Yanting Huang , Aimin Yang , Mai Shi , Jiazhou Yu , Hongjiang Wu , Juliana N.M. Lui , Alice P.S. Kong , Ronald C.W. Ma , Andrea O.Y. Luk , Calvin Ke , Juliana C.N. Chan , Elaine Chow
{"title":"Trends of lipid-lowering drug utilization, treatment intensity and LDL-C target attainment in adults with diabetes and non-dialysis chronic kidney disease in Hong Kong","authors":"Yanting Huang ,&nbsp;Aimin Yang ,&nbsp;Mai Shi ,&nbsp;Jiazhou Yu ,&nbsp;Hongjiang Wu ,&nbsp;Juliana N.M. Lui ,&nbsp;Alice P.S. Kong ,&nbsp;Ronald C.W. Ma ,&nbsp;Andrea O.Y. Luk ,&nbsp;Calvin Ke ,&nbsp;Juliana C.N. Chan ,&nbsp;Elaine Chow","doi":"10.1016/j.lanwpc.2025.101696","DOIUrl":"10.1016/j.lanwpc.2025.101696","url":null,"abstract":"<div><h3>Background</h3><div>With evolving treatment targets, concerns over renal safety for some statins and new lipid-lowering drugs (LLDs), we aimed to evaluate the trends of statins and non-statin LLDs [ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)] utilization in individuals with diabetes and non-dialysis chronic kidney disease (CKD) in Hong Kong.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of 332,975 Chinese individuals with diabetes and non-dialysis CKD using data from Hong Kong Hospital Authority in 2002–2019. We analyzed the annual average dosage, treatment intensity (low-intensity: &lt;30% Low density lipoprotein-cholesterol (LDL-C) reduction; moderate-intensity: 30%–49%; high-intensity: ≥50%) and attained LDL-C targets defined by annual average LDL-C value. We evaluated the age-sex standardized trends of statin and common non-statin LLD use for primary and secondary prevention across age, sex and CKD stages.</div></div><div><h3>Findings</h3><div>Statin-users increased from 17.6% in 2002 to 71.3% in 2019 with similar trends across age, sex and CKD stages G3–5 except for the 18–49 age group having the highest proportion of non-users of LLD (39%). By 2019, the usage of ezetimibe (1.19%) and PCSK9i (0.01%) remained low. Amongst statin-users, 27.2% received moderate-intensity therapy for primary prevention and 11.2% received high-intensity therapy for secondary prevention. In 2019, 33.3% of LLD-users achieved LDL-C &lt; 1.8 mmol/L for primary prevention and 21.3% achieved LDL-C &lt; 1.4 mmol/L for secondary prevention.</div></div><div><h3>Interpretation</h3><div>Despite the increasing use of statins, treatment gaps remain with respect to treatment intensity and LDL-C target attainment in diabetes and non-dialysis CKD calling for increased use of combination statin and ezetimibe or PCSK9i to close the treatment gaps.</div></div><div><h3>Funding</h3><div>Dr. Aimin Yang was supported by a <span>CUHK Impact Research Fellowship Scheme</span>.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101696"},"PeriodicalIF":8.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sociodemographic heterogeneity in the association between social isolation and all-cause mortality among Japanese older adults: JAGES longitudinal panel study 日本老年人社会孤立与全因死亡率之间的社会人口异质性:JAGES纵向面板研究
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-10-01 DOI: 10.1016/j.lanwpc.2025.101691
Frances Rom Lunar , Naoki Kondo , Yukiko Honda , Atsushi Nakagomi , Toshiaki Komura , Kosuke Inoue , Koichiro Shiba
{"title":"Sociodemographic heterogeneity in the association between social isolation and all-cause mortality among Japanese older adults: JAGES longitudinal panel study","authors":"Frances Rom Lunar ,&nbsp;Naoki Kondo ,&nbsp;Yukiko Honda ,&nbsp;Atsushi Nakagomi ,&nbsp;Toshiaki Komura ,&nbsp;Kosuke Inoue ,&nbsp;Koichiro Shiba","doi":"10.1016/j.lanwpc.2025.101691","DOIUrl":"10.1016/j.lanwpc.2025.101691","url":null,"abstract":"<div><h3>Background</h3><div>Social isolation has been linked to higher mortality; however, it remains unknown how this association varies across individuals and social groups.</div></div><div><h3>Methods</h3><div>We used a nationwide cohort study of ∼20,000 older adults with a 9·4-year follow-up period (Japan Gerontological Evaluation Study, 2013–2022), adjusting for 60 pre-baseline covariates. We also used a national insurance database to ascertain 4299 all-cause deaths. Using a causal machine-learning method, we estimated the heterogeneous association between social isolation and mortality.</div></div><div><h3>Findings</h3><div>Social isolation was more prevalent among those with lower education and income and associated on average with 69·5-day shorter survival time (restricted mean survival time [RMST] difference; 95% CI: −111, −28·4). There was evidence of heterogeneity where social isolation was associated with even shorter survival days in some subgroups (e.g., −205 days among the bottom quintile of the estimated RMST differences [95% CI: −321, −87·8]). These subgroups tended to be older, men, and have lower education. The adverse association of social isolation and mortality was particularly stronger when lower education was combined with higher income, especially among women. Individuals with lower levels of education accounted for a larger share of deaths attributable to social isolation (58·5% of excess deaths).</div></div><div><h3>Interpretation</h3><div>Social isolation may be more harmful among those from socially disadvantaged backgrounds, and a combination of some characteristics can synergistically amplify its effects on mortality. Proper population-level interventions informed with the evidence of effect heterogeneity might not only improve health on average but also mitigate existing health disparities.</div></div><div><h3>Funding</h3><div><span>Japan Society for the Promotion of Science</span>, <span>Health Labour Sciences Research Grants</span>, <span>Research Funding for Longevity Sciences from the National Center for Geriatrics and Gerontology</span>, Research Institute of Science and Technology from the <span>Japan Science and Technology</span>, <span>Japan Health Promotion &amp; Fitness Foundation</span>, <span>Department of Active Ageing</span>, <span>Niigata University Graduate School of Medical and Dental Sciences</span>, Tokyo Medical and Dental University Priority Research Areas Grant and National Research Institute for Earth Science and Disaster Resilience.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101691"},"PeriodicalIF":8.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving support for people with mental health problems in China: a cluster randomised controlled trial of culturally adapted Mental Health First Aid training 改善对中国精神健康问题患者的支持:一项文化适应精神健康急救培训的随机对照试验
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-10-01 DOI: 10.1016/j.lanwpc.2025.101698
Nicola Reavley , Amy J. Morgan , Anthony F. Jorm , Betty Kitchener , Yan Wang , Shurong Lu , Wenjing Li , Claire Kelly , Brian Oldenburg , Min Zhao , Yanling He
{"title":"Improving support for people with mental health problems in China: a cluster randomised controlled trial of culturally adapted Mental Health First Aid training","authors":"Nicola Reavley ,&nbsp;Amy J. Morgan ,&nbsp;Anthony F. Jorm ,&nbsp;Betty Kitchener ,&nbsp;Yan Wang ,&nbsp;Shurong Lu ,&nbsp;Wenjing Li ,&nbsp;Claire Kelly ,&nbsp;Brian Oldenburg ,&nbsp;Min Zhao ,&nbsp;Yanling He","doi":"10.1016/j.lanwpc.2025.101698","DOIUrl":"10.1016/j.lanwpc.2025.101698","url":null,"abstract":"<div><h3>Background</h3><div>Culturally appropriate interventions that teach members of the public to provide early help towards a person developing a mental health problem or in a mental health crisis may improve access to services, social support, and mental health outcomes. This is the first study to evaluate the effectiveness of culturally adapted Mental Health First Aid (MHFA) Training for China.</div></div><div><h3>Methods</h3><div>A two-arm wait-list pilot cluster randomised controlled trial (cRCT) was conducted in 3 settings in Shanghai (health services, workplaces and community settings). Intervention settings were paired according to type and one of each pair was randomly allocated to the intervention (MHFA Training for China) or the wait-list control group, with a 1:1 allocation. Participants were invited by the trial coordinators in each setting. They were asked to complete questionnaires at baseline (T1) and 1 month (T2) and 7 months after training (T3). Control group participants were asked to complete questionnaires at corresponding times. The primary outcome was participant intended actions (recommended or not recommended) towards a person experiencing a mental health problem or in a mental health crisis. Secondary outcomes included recognition of depression in a vignette; beliefs about the helpfulness of health professionals and interventions; helping actions; confidence in providing mental health first aid; and stigmatising attitudes.</div></div><div><h3>Findings</h3><div>Between April and May 2024, 6 clusters were recruited and randomised, with 3 in each of the intervention and control arms. Following exclusion of participants who did not provide data, 146 participants were included at baseline: 67 in the intervention group and 79 in the control group. For the primary outcome (recommended actions subscale), the intervention group showed a significantly larger improvement than the control group at T2 (8.19 [95% CI 4.05–12.34]; p &lt; 0.001) and T3 (3.08 [95% CI −1.02 to 7.18]; p = 0.034). Differences in changes in non-recommended actions were non-significant. At T2, significant differences favouring the intervention group were observed in confidence to provide support, perceiving the person as dangerous or unpredictable and in recognition of depression in a vignette. There were no significant differences in secondary outcomes at T3.</div></div><div><h3>Interpretation</h3><div>Delivering culturally adapted MHFA Training for China more widely could improve support for people experiencing mental health problems in the community.</div></div><div><h3>Funding</h3><div>This trial was supported the <span>National Health and Medical Research Council</span> under a <span>Global Alliance for Chronic Diseases</span> grant (<span><span>GNT1142395</span></span>).</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101698"},"PeriodicalIF":8.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study Lancet Reg Health West Pac (2023) 38: 100846 一项比较自身抗体诊断方法在重症肌无力中的准确性的多中心、前瞻性、双盲研究的勘误表:SCREAM研究Lancet Reg Health West Pac (2023) 38: 100846
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-10-01 DOI: 10.1016/j.lanwpc.2025.101665
Zhiguo Li , Chao Zhang , Ting Chang , Xinghu Zhang , Huan Yang , Feng Gao , Jinzhou Feng , Hongbo Liu , Sheng Chen , Lihua Wang , Chunsheng Yang , Huining Li , Yuesong Pan , Jacqueline Palace , Fu-Dong Shi
{"title":"Corrigendum to A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study Lancet Reg Health West Pac (2023) 38: 100846","authors":"Zhiguo Li ,&nbsp;Chao Zhang ,&nbsp;Ting Chang ,&nbsp;Xinghu Zhang ,&nbsp;Huan Yang ,&nbsp;Feng Gao ,&nbsp;Jinzhou Feng ,&nbsp;Hongbo Liu ,&nbsp;Sheng Chen ,&nbsp;Lihua Wang ,&nbsp;Chunsheng Yang ,&nbsp;Huining Li ,&nbsp;Yuesong Pan ,&nbsp;Jacqueline Palace ,&nbsp;Fu-Dong Shi","doi":"10.1016/j.lanwpc.2025.101665","DOIUrl":"10.1016/j.lanwpc.2025.101665","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101665"},"PeriodicalIF":8.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial 新辅助奇达胺联合化疗治疗激素受体阳性、人表皮生长因子受体2阴性乳腺癌(MUKDEN 05):一项多中心、单臂、2期试验
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-09-27 DOI: 10.1016/j.lanwpc.2025.101700
Jinqi Xue , Huilian Shan , Fang Qiu , Nan Niu , Guanglei Chen , Qianshi Xu , Xi Gu , Fei Xing , Yongqing Xu , Xinyu Zheng , Guijin He , Hong Xu , Hao Zhang , Dong Song , Ye Han , Meiyue Tang , Shuo Cao , Yang Song , Ran Zheng , Yafei Zhao , Caigang Liu
{"title":"Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial","authors":"Jinqi Xue ,&nbsp;Huilian Shan ,&nbsp;Fang Qiu ,&nbsp;Nan Niu ,&nbsp;Guanglei Chen ,&nbsp;Qianshi Xu ,&nbsp;Xi Gu ,&nbsp;Fei Xing ,&nbsp;Yongqing Xu ,&nbsp;Xinyu Zheng ,&nbsp;Guijin He ,&nbsp;Hong Xu ,&nbsp;Hao Zhang ,&nbsp;Dong Song ,&nbsp;Ye Han ,&nbsp;Meiyue Tang ,&nbsp;Shuo Cao ,&nbsp;Yang Song ,&nbsp;Ran Zheng ,&nbsp;Yafei Zhao ,&nbsp;Caigang Liu","doi":"10.1016/j.lanwpc.2025.101700","DOIUrl":"10.1016/j.lanwpc.2025.101700","url":null,"abstract":"<div><h3>Background</h3><div>Existing neoadjuvant therapies for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer have not achieved optimal clinical outcomes, thus prompting the investigation of novel treatment strategies. Given the emerging significance of HDAC inhibitors in the management of advanced breast cancer, this study investigated the efficacy and safety of chidamide plus chemotherapy as neoadjuvant therapy for patients with HR+/HER2− breast cancer.</div></div><div><h3>Methods</h3><div>This single arm, open-label, multicentre, phase 2 trial was conducted at three hospitals in China. Patients aged 18–75 years who had treatment-naïve, stage II–III HR+/HER2− breast cancer with an Eastern Cooperative Oncology Group performance status of 0–1 were enrolled. Patients received oral chidamide at a dose of 20 mg on days 1, 4, 8, and 11 of each 21-day cycle. The chemotherapy regimen consisted of four cycles of epirubicin (90 mg/m<sup>2</sup>) and cyclophosphamide (600 mg/m<sup>2</sup>) administered every three weeks, followed by four cycles of docetaxel (100 mg/m<sup>2</sup>) administered every three weeks. The primary endpoint was the rate of residual cancer burden (RCB) 0–I. This study is registered with <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, <span><span>NCT05400993</span><svg><path></path></svg></span>.</div></div><div><h3>Findings</h3><div>Between May 23, 2022 and July 6, 2023, a total of 54 female patients (median age: 50 years [range, 26–75]) were recruited. The RCB 0–I rate was 35.2% (19 of 54, 95% confidence interval [CI], 22.7%–49.4%). The most frequent grade 3 or 4 adverse events were decreased neutrophil count (70%) and decreased white blood cell (67%). No treatment-related deaths occurred.</div></div><div><h3>Interpretation</h3><div>The combination of chidamide and chemotherapy shows the potential to be an alternative neoadjuvant therapy option for patients with HR+/HER2− breast cancer.</div></div><div><h3>Funding</h3><div><span>Shenyang Municipal Science and Technology Program</span> (Grant No. <span><span>22-321-32-18</span></span>), Shenzhen Chipscreen Biosciences Co., Ltd.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101700"},"PeriodicalIF":8.1,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145159943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of COVID-19 pandemic on cognitive decline in community-dwelling older adults in Shanghai: a longitudinal study from 2010 to 2024 新冠肺炎大流行对上海市社区老年人认知能力下降的影响:2010 - 2024年的纵向研究
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-09-26 DOI: 10.1016/j.lanwpc.2025.101697
Xiaowen Zhou , Hanzhi Deng , Hanyu Shao , Tao Yang , Yuntao Chen , Yang Cao , Qianhua Zhao , Ding Ding
{"title":"Impact of COVID-19 pandemic on cognitive decline in community-dwelling older adults in Shanghai: a longitudinal study from 2010 to 2024","authors":"Xiaowen Zhou ,&nbsp;Hanzhi Deng ,&nbsp;Hanyu Shao ,&nbsp;Tao Yang ,&nbsp;Yuntao Chen ,&nbsp;Yang Cao ,&nbsp;Qianhua Zhao ,&nbsp;Ding Ding","doi":"10.1016/j.lanwpc.2025.101697","DOIUrl":"10.1016/j.lanwpc.2025.101697","url":null,"abstract":"<div><h3>Background</h3><div>In 2022, the rapid spread of the highly transmissible Omicron variant precipitated a dramatic surge in infections and a subsequent societal shutdown in Shanghai. It offers the opportunity to examine the impact of COVID-19 pandemic on cognitive decline among community-dwelling older adults.</div></div><div><h3>Methods</h3><div>The Shanghai Aging Study enrolled 3792 community residents aged ≥ 50 from 2010 to 2012 in central Shanghai. Demographics, medical history, ApoE genotyping, and plasma phosphorylated tau 217 (p-tau217), phosphorylated tau 181 (p-tau181), and neurofilament light chain (NfL) were collected at baseline. Cognitive function assessment and MRI scans were conducted at baseline and follow-up visits from 2014 to 2024. Study periods were defined as Wave 1 (Jan.2010–Dec.2012, baseline, pre-pandemic), Wave 2 (Jan.2014–Mar.2022, pre-pandemic), and Wave 3 (Jun.2022–Dec.2024, post-pandemic). Event study, difference-in-differences (DID), and linear mixed-effects models were employed to evaluate the pandemic’s impact on cognitive trajectories and brain structural changes.</div></div><div><h3>Findings</h3><div>We observed steeper age-related declines of the Mini-Mental State Examination (MMSE) during Wave 3. The event study model adjusting for age, sex, and education, showed significant MMSE decline in Wave 3, but not in Wave 2. Declines were more pronounced in individuals with high baseline plasma p-tau217, p-tau181, and NfL, ApoE-ε4 carriers, those with multi-comorbidities, or long-term medication use. The DID and linear mixed-effects models with individual-specific follow-up data revealed accelerated declines in global cognition, executive and language function, and structural brain atrophy from Wave 2–3, compared with Wave 1–2.</div></div><div><h3>Interpretation</h3><div>The COVID-19 pandemic significantly accelerated cognitive and brain structural changes in community-dwelling older adults, particularly among those with pre-existing AD pathology or health vulnerabilities. These findings provide evidence of COVID-19 pandemic-related cognitive decline and highlight the need for mechanistic research into how direct and indirect stressors converge to drive cognitive impairment.</div></div><div><h3>Funding</h3><div><span>National Natural Science Foundation of China</span>, <span>Tianqiao and Chrissy Chen Institute</span>, <span>China National Postdoctoral Committee Fund</span>, <span>UCL</span>: Wellcome Early-Career Award and Royal Society.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101697"},"PeriodicalIF":8.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145159896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining the association of triglycerides with all-cause and Cardiovascular Disease Mortality in the Chinese population: a nationwide, population-based, prospective cohort study of 3.8 million Chinese adults 重新定义甘油三酯与中国人群全因和心血管疾病死亡率的关系:一项380万中国成年人的全国性、基于人群的前瞻性队列研究
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-09-25 DOI: 10.1016/j.lanwpc.2025.101689
Guangyu Li , Linkang He , Xueke Bai , Shi Chen , Hao Dai , Guangda He , Yang Yang , Xiaoyan Zhang , Jianlan Cui , Xi Li , Chris Packard , Jan Boren , Liang Chen , Shengshou Hu
{"title":"Redefining the association of triglycerides with all-cause and Cardiovascular Disease Mortality in the Chinese population: a nationwide, population-based, prospective cohort study of 3.8 million Chinese adults","authors":"Guangyu Li ,&nbsp;Linkang He ,&nbsp;Xueke Bai ,&nbsp;Shi Chen ,&nbsp;Hao Dai ,&nbsp;Guangda He ,&nbsp;Yang Yang ,&nbsp;Xiaoyan Zhang ,&nbsp;Jianlan Cui ,&nbsp;Xi Li ,&nbsp;Chris Packard ,&nbsp;Jan Boren ,&nbsp;Liang Chen ,&nbsp;Shengshou Hu","doi":"10.1016/j.lanwpc.2025.101689","DOIUrl":"10.1016/j.lanwpc.2025.101689","url":null,"abstract":"<div><h3>Background</h3><div>Current international guidelines on dyslipidemia were formulated based on the research performed mostly in White populations. However, whether the association of triglycerides (TGs) with cardiovascular disease (CVD) differs between Chinese and White populations is unknown.</div></div><div><h3>Methods</h3><div>3,789,025 participants from the China Health Evaluation And risk Reduction through nationwide Teamwork (ChinaHEART) were evaluated for the association between TGs and all-cause and CVD mortality with Cox regression models. The findings were tested for sex-specific differences and contrasted with another comparison cohort of 434,919 UK Biobank participants.</div></div><div><h3>Findings</h3><div>92,888 Chinese adults died during a median follow-up of 4.6 years. All-cause and CVD mortality initially increased with TG elevation abruptly and plateaued in Chinese men, while U-shaped associations were seen in Chinese women. In contrast, CVD risk increased incrementally with TGs in White people. Hazard ratios (95% confidence intervals) were 1.02 (0.97–1.07), 1.05 (1.00–1.11), 1.07 (1.02–1.22), and 1.19 (1.13–1.24) from TG quintile 2 to 5 for White men, and 1.14 (1.08–1.21), 1.17 (1.11–1.24), 1.26 (1.18–1.33), and 1.41 (1.33–1.50) for White women, respectively. The association with CVD mortality was stronger in Chinese men who were lean, normotensive, and smoking but in Chinese women with diabetes.</div></div><div><h3>Interpretation</h3><div>The association of TGs with CVD was different for the White and the Chinese populations. That mortality risk elevated in conventionally low-to-moderate TG range implicates that more aggressive intervention may be merited for Chinese and other East Asian populations.</div></div><div><h3>Funding</h3><div>The <span>National High Level Hospital Clinical Research</span> Funding (2023-GSP-ZD-2, 2023-GSP-RC-01), the <span>Ministry of Finance</span>, and the <span>National Health Commission</span> of China.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101689"},"PeriodicalIF":8.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145159944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bangkok declarations on cancer control in Asia 亚洲癌症控制曼谷宣言
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-09-22 DOI: 10.1016/j.lanwpc.2025.101690
Junjie Huang , Claire Chenwen Zhong , Abubakar Sunusi Ishak , Bukola Titilope Lawal , Chidinma Nelson Orji , Edmar S. Elcarte , Onyeka Emmanuel Obukishie , Paolo Miguel Manalang Vicerra , Romruedee Phisalaphong , Soe Thiha Maung , Yue Suo , Zhengwei Huang , Zehuan Yang , Taninee Sahakitrungruang , Sanjay Rampal , Mellissa Withers , Martin C.S. Wong , NCD Global Health Working Group of Association of Pacific Rim Universities (APRU)
{"title":"Bangkok declarations on cancer control in Asia","authors":"Junjie Huang ,&nbsp;Claire Chenwen Zhong ,&nbsp;Abubakar Sunusi Ishak ,&nbsp;Bukola Titilope Lawal ,&nbsp;Chidinma Nelson Orji ,&nbsp;Edmar S. Elcarte ,&nbsp;Onyeka Emmanuel Obukishie ,&nbsp;Paolo Miguel Manalang Vicerra ,&nbsp;Romruedee Phisalaphong ,&nbsp;Soe Thiha Maung ,&nbsp;Yue Suo ,&nbsp;Zhengwei Huang ,&nbsp;Zehuan Yang ,&nbsp;Taninee Sahakitrungruang ,&nbsp;Sanjay Rampal ,&nbsp;Mellissa Withers ,&nbsp;Martin C.S. Wong ,&nbsp;NCD Global Health Working Group of Association of Pacific Rim Universities (APRU)","doi":"10.1016/j.lanwpc.2025.101690","DOIUrl":"10.1016/j.lanwpc.2025.101690","url":null,"abstract":"<div><div>The “Bangkok Declarations” highlight key strategies to reduce the cancer burden in Asia. Recognizing the role of lifestyle factors like tobacco use, unhealthy diets, and inactivity, they advocate for public health initiatives promoting healthier communities. Environmental risks must also be addressed to enhance prevention strategies. Vaccination programs targeting cancer-causing viruses are emphasized for reducing incidence rates. However, limited access to cancer screening and early detection services remains a challenge, requiring improvements to boost early intervention and patient outcomes. The financial burden of cancer treatment is critical, necessitating cost-effective therapies and financial support systems. Mental health support for patients and caregivers is essential for holistic care. Digital health technologies and AI offer promise for improving diagnosis and treatment in resource-limited settings. Collaboration among stakeholders is vital, with culturally sensitive approaches ensuring equitable care. Research should focus on lifestyle, environmental factors, innovative prevention, and access to care for effective cancer control.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101690"},"PeriodicalIF":8.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145120664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Communicable diseases genomics network: promoting and harmonising pathogen genomics implementation for public health in Australia 传染病基因组学网络:促进和协调澳大利亚公共卫生病原体基因组学的实施
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-09-22 DOI: 10.1016/j.lanwpc.2025.101692
Chantel Lin , Amy V. Jennison , Lex E.X. Leong , David J. Speers , Ella M. Meumann , Louise Cooley , Karina Kennedy , Alicia Arnott , David Winter , William Rawlinson , Jennifer Robson , Patrick Harris , Angela Donald , Torsten Seemann , Susan A. Ballard , Martyn Kirk , Vitali Sintchenko , Deborah A. Williamson , Benjamin P. Howden , Communicable Diseases Genomics Network
{"title":"Communicable diseases genomics network: promoting and harmonising pathogen genomics implementation for public health in Australia","authors":"Chantel Lin ,&nbsp;Amy V. Jennison ,&nbsp;Lex E.X. Leong ,&nbsp;David J. Speers ,&nbsp;Ella M. Meumann ,&nbsp;Louise Cooley ,&nbsp;Karina Kennedy ,&nbsp;Alicia Arnott ,&nbsp;David Winter ,&nbsp;William Rawlinson ,&nbsp;Jennifer Robson ,&nbsp;Patrick Harris ,&nbsp;Angela Donald ,&nbsp;Torsten Seemann ,&nbsp;Susan A. Ballard ,&nbsp;Martyn Kirk ,&nbsp;Vitali Sintchenko ,&nbsp;Deborah A. Williamson ,&nbsp;Benjamin P. Howden ,&nbsp;Communicable Diseases Genomics Network","doi":"10.1016/j.lanwpc.2025.101692","DOIUrl":"10.1016/j.lanwpc.2025.101692","url":null,"abstract":"<div><div>Globally, the utility of pathogen genomics for public health was highlighted by the COVID-19 pandemic. Approaches to enhance coordination and improve implementation of pathogen genomics for public health are needed. The Communicable Diseases Genomics Network (CDGN) was established in 2015 in Australia. The network, embedded at the public health laboratory interface and supported by the Australian Government, has facilitated a coordinated model in Australia for public health pathogen genomics. CDGN activities have facilitated pilot projects to demonstrate use cases, harmonisation of data sharing and governance arrangements, outbreak and pandemic response, translational research, policy development and workforce capacity building. The impact of CDGN has been enabling the significant progress towards public health genomics implementation in Australia, and providing a model that could be applied in other federated settings, aligned with international best practice.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101692"},"PeriodicalIF":8.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145120665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019–2024 阿托伐他汀治疗慢性硬膜下血肿的特点和结果:2019-2024年在中国进行的一项全国性、观察性现实世界研究
IF 8.1 1区 医学
The Lancet Regional Health: Western Pacific Pub Date : 2025-09-18 DOI: 10.1016/j.lanwpc.2025.101688
Tao Liu , Zhihao Zhao , Jiao Wang , Xiaoying Chen , Jinhao Huang , Weiwei Jiang , Yunhu Yu , Xide Zhu , Kaijie Wang , Kun Lin , Hu Qin , Baixiang Peng , Guohe Zhang , Zhiyong Liu , Weiliang Chen , Jun Shen , Baozhi Chen , Shengjie Li , Mingqi Liu , Wanqiang Su , Craig S. Anderson
{"title":"Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019–2024","authors":"Tao Liu ,&nbsp;Zhihao Zhao ,&nbsp;Jiao Wang ,&nbsp;Xiaoying Chen ,&nbsp;Jinhao Huang ,&nbsp;Weiwei Jiang ,&nbsp;Yunhu Yu ,&nbsp;Xide Zhu ,&nbsp;Kaijie Wang ,&nbsp;Kun Lin ,&nbsp;Hu Qin ,&nbsp;Baixiang Peng ,&nbsp;Guohe Zhang ,&nbsp;Zhiyong Liu ,&nbsp;Weiliang Chen ,&nbsp;Jun Shen ,&nbsp;Baozhi Chen ,&nbsp;Shengjie Li ,&nbsp;Mingqi Liu ,&nbsp;Wanqiang Su ,&nbsp;Craig S. Anderson","doi":"10.1016/j.lanwpc.2025.101688","DOIUrl":"10.1016/j.lanwpc.2025.101688","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The incidence of chronic subdural hematoma (cSDH) is increasing in the aging population worldwide, where the success of conventional surgical decompression is complicated by high rates of complications and recurrence. The anti-inflammatory properties of atorvastatin make it an attractive, low-cost, and safe medical approach, but limited evidence exists regarding its clinical benefit in cSDH. We aim to evaluate temporal trends, disease characteristics, and clinical outcomes associated with atorvastatin treatment for cSDH in real-world settings in China.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This was a multicenter registry study of the Chronic Subdural Hematoma (MR-CSDH) in China. Adults received either 20 mg of atorvastatin or not daily for 8 weeks and were followed up for an additional 6 months at 61 medical centers between November 1, 2019 and October 30, 2024. The primary outcome was good functional outcome defined by modified Rankin scale scores of 0–3 at 6 months. Secondary outcomes included good clinical outcomes and recurrence at 3 months, mortality and recurrent SDH at 6 months, healthcare costs, suspected statin-related adverse events, and length of hospital stay. Logistic regression and propensity score matching (PSM) were used for analysis. The trial was registered with Chinese Clinical Trial Registry, identifier ChiCTR2200057179.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;A total of 2422 patients were included (mean [SD] age: 70.3 [14.5] years; 453 [18.7%] female), of whom 1777 (73.4%) received atorvastatin therapy. The proportion of cSDH patients receiving conservative treatment tripled, rising from 14.7% in 2019 to 53.4% in 2024 (P for trend &lt;0.001), while the proportion undergoing surgical treatment significantly declined (P &lt; 0.001). Moreover, the proportion of cSDH patients prescribed statin medication showed a steady temporal increase. Compared to patients who did not receive atorvastatin, those treated with atorvastatin had a higher likelihood of good functional outcome (odds ratio 1.93, 95% confidence interval [CI] 1.29–2.89), lower risk of mortality (hazard ratio 0.24, 95% CI 0.06–0.92) at 6 months, and reduced length of hospital stay (mean difference [MD] −1.69, 95% CI [−3.01, −0.37], P = 0.012) and decreased hospitalization costs (MD −0.79, 95% CI [−1.31, −0.28], P = 0.003). However, the between-group differences in recurrent SDH (at 3 and 6 months) and adverse events were not significantly different.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;This study indicates a positive association between atorvastatin use and good clinical outcomes in patients with cSDH, and is increasingly being used in China.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;This study was funded by the &lt;span&gt;National Natural Science Foundation of China&lt;/span&gt; (No. &lt;span&gt;&lt;span&gt;82071390&lt;/span&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;82001323&lt;/span&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;82101434&lt;/span&gt;&lt;/span&gt;), the &lt;span&gt;Science and Technology Project of Tianjin&lt;/span&gt; (No","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"63 ","pages":"Article 101688"},"PeriodicalIF":8.1,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信